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Abstract
Background: Orthotopic liver transplantation (OLT) may be associated with massive blood loss and the need for allogenic
blood product transfusions. Cell salvage autotransfusion (CS) is an attractive alternative to allogenic red blood cell (RBC)
transfusion. However, controversy surrounds its usefulness during OLT; some studies stated that CS decreased transfusions
of allogenic blood products and others stated that blood loss was increased. The aim of this study was to evaluate the efficiency
of the CS during OLT. Patients and methods: After approval by the institutional ethics committee, a prospective survey was
undertaken. A total of 150 consecutive OLTs were included in the study. Two groups of patients were formed. Period
1 included patients 175 with no CS use. Period 2 comprised patients 76150 with systematic CS use. Results: Patients from
both periods were comparable. CS was used in all cases in period 2, and there was enough salvaged blood to retransfuse 65%
of these OLTs. The mean volume of retransfused blood was 3389/339 ml. The transfusion rate did not change from period
1 to period 2. The mean number of RBC units transfused per patient was 0.49/0.9 vs 0.49/1.2 with 78.7% vs 81.3% of cases
not receiving transfusion of any blood product. The threshold for RBC transfusions was the same. The length of surgery and
blood loss were greater in period 2 than in period 1 (associated with the arrival of two junior surgeons), but the hemoglobin
(Hb) value was also higher at the end of surgery (93.89/19.3 g/L vs 85.29/17.8 g/L, pB/0.0001). Conclusion: Despite
increased blood loss in period 2, CS saved 21 g/L of Hb per patient or two RBC unit transfusions. As long as we cannot predict
with accuracy which patients will bleed, we will continue to use the CS for all OLTs.
Key Words: liver transplantation, transfusion, cell salvage autotransfusion
Introduction
Orthotopic liver transplantation (OLT) could be
associated with major blood loss and the need for
allogenic blood product transfusion. During the last 20
years, a large and constant decrease in blood loss and
blood product requirements has been observed, redu-
cing from as much as 43 red blood cell (RBC) units [1]
to only 0.3 RBC units per patient [2]. Improvements in
surgical technique, the use of anti-fibrinolytic agents
[35], and the development of new anesthetic strate-
gies (low central venous pressure (CVP), phlebotomy)
[2,6] have contributed to steady reductions in blood
loss and in transfusion needs during OLT.
Cell salvage autotransfusion (CS) is an attractive
alternative to allogenic RBC transfusions. Neverthe-
less, controversy has arisen over its use during OLT
because some studies have stated that the CS has
reduced allogenic RBC transfusion requirements, and
that its use is safe [711]. Others, however, have
reported higher blood losses through fibrinolysis with
the CS or found that it was not cost-effective [1214].
The controversy could persist because these studies
were retrospective or observational and there was
some confusion between OLT from living donors and
cadavers.
In view of the arrival of two junior surgeons in
our center, we hypothesized that the length of surgery
would increase, as would blood loss. The purpose
of this survey was to assess CS efficiency to reduce
or limit allogenic RBC requirements during OLT.
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Patients and methods
After approval from the Ethics Committee of the
CHUM-Hoˆpital St-Luc, a prospective survey (study
with historical controls) [15] was undertaken. A total
of 150 consecutive OLTs from cadaver donors,
starting in 2002, were included. Two groups of
patients were formed: period 1, patients 175 without
CS use; and period 2, patients 76150 where CS was
used systematically for every OLT. The only contra-
indications were intra-abdominal infection or abscess.
Surgical protocol
Four surgeons were involved in the historic period and
six in the prospective one, with two of them partici-
pating in each procedure. Complete classical cross-
clamping of the suprahepatic and infrahepatic vena
cava and the portal vein were used without any veno-
venous bypass nor piggyback technique. All liver
procurements were from cadaver donors and were
ABO-Rh compatible. Regular steroid induction fol-
lowed by maintenance therapy with tacrolimus was
used.
Anesthetic protocol
Thirteen anesthesiologists were involved in OLTs
during the study period. Monitoring and anesthesia
were standardized [6]. Coagulation defects were not
corrected upon laboratory data in the absence of
uncontrollable bleeding. The threshold for RBC
transfusions was set at a hemoglobin (Hb) value of
68 g/L [6], and an effort was made not to start any
transfusion until the blood losses were controlled.
Aprotinin was given to every patient according to the
Hammersmith protocol [16]. Patients underwent
serial arterial blood gas analysis which included Hb,
potassium, and ionized calcium measurements. Coa-
gulation was monitored as needed intraoperatively
(INR, platelet count). No plasma (fresh frozen
plasma) or platelets were to be transfused, unless
there was uncontrollable bleeding (diffuse oozing
without any clinical coagulation) when the American
Society of Anesthesiology (ASA) guidelines [17] were
met (on starting biochemical values).
Each anesthesiologist lowered baseline CVP before
the anhepatic phase by about 40% by restricting
volume infusion, by phlebotomy without volume
replacement, or by a combination of both techniques
[6]. Harvested blood was returned to the patient at
the end of the surgery or before as needed.
Cell salvage autotransfusion
The Fresenius CATS (Continuous Autotransfusion
System) device was used for all OLTs during period 2
(only in the operating room). After collecting blood
lost in the reservoir from the operating field, the
perfusionist calculated the quantity of blood to permit
its retransfusion with hematocrit (Ht) above 0.7 after
washing and concentration of the harvested blood.
If the quantity calculated was higher than 40 ml, the
collected blood was washed, concentrated, and re-
transfused to the patient.
In conclusion, surgical and anesthesiologic techni-
ques were the same in both periods, except for
systematic use of the CS, and the arrival of two young
surgeons in period 2.
Statistical analysis
The data are expressed as mean9/standard deviation
(SD) of the mean, and as percentages or absolute
numbers. Distributions were examined to ensure
proper statistical evaluation. Statistical analysis was
performed by Student’s t test or Welch’s t test as
appropriate. The x2 test was used to compare
percentages. p values B/0.05 were considered signifi-
cant. SPSS 10 statistical programs were implemented.
Results
In all, 150 OLTs were performed on 135 patients.
Nine patients had two OLTs, three patients had three,
and five patients had already undergone an OLT
before the study period.
The mean number of intraoperative allogenic RBC
units transfused per patient was 0.49/1.0 (median 0,
maximum 8) (Figure 1); five units of plasma were
transfused to two patients, and five units of platelets
to one patient. No albumin or cryoprecipitate was
transfused. One hundred and twenty patients (80%)
received no allogenic blood products during their
OLT, and the final Hb was 89.59/19.0 g/L. Table I
presents the demographic characteristics and health
status of patients for each period. Both groups were
virtually the same. Table II enumerates the periopera-
tive data for each group. During period 2, the CS was
used for each OLT, but there was enough blood
salvage to retransfuse 65% of the cases. The mean
volume of retransfused blood was 3389/339 ml with a
minimum of 40 ml, a maximum of 2000 ml, and a
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Figure 1. Patient stratification by number of intraoperative RBC
units transfused for all patients.
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median of 256 ml. For both periods, phlebotomy was
undertaken in 42% of the cases and 6169/227 ml of
blood were withdrawn (minimum 300 ml, maximum
1200 ml) and the blood was retransfused at the end
of the case. The length of surgery was greater in
period 2 than in period 1 (2669/68 min vs 2259/57
min, pB/0.0001), as was the amount of blood lost
(14109/603 ml vs 8189/302 ml, pB/ 0.0001).
CVP values before clamping the vena cava were the
same in both periods (6.99/4.2 mmHg vs 5.89/2.5
mmHg). The transfusion rate was the same for each
period: the number of RBC units transfused per
patient (0.49/0.9 vs 0.49/1.2), the percentage of
cases without transfusion of any blood products
(78.7% vs 81.3%) (Figures 2 and 3), and the thresh-
old for RBC transfusion (57.09/7.5 g/L vs 55.79/8.6
g/L) (Table II). The final Hb value was higher
in period 2 (93.8 9/19.3 g/L vs 85.29/17.8 g/L,
pB/0.0001).
Surgeons 5 and 6 (two junior surgeons returning
from their fellowship) joined the team of four sur-
geons during period 2. They performed 20 and 10
OLTs, respectively. Table III gives some of the
variables for two groups of surgeons: seniors vs
juniors. Length of surgery and blood loss were greater
with the two junior surgeons compared with the
senior surgeons but the transfusion rates were the
same (0.39/0.7 RBC units per patient vs 0.49/1.3
RBC units per patient). The diagnostic classification
of patients in both periods can be found in Table IV.
Discussion
This prospective survey does not pretend to be
randomized with a control group where CS was
evaluated in two groups with the same blood loss. In
view of the established low rate of blood product
transfusions in our center, we thought that it was
unethical to create a control group that would have
been at increased risk of receiving blood products. If
we were allowed to conduct a prospective randomized
study with a control group, to determine if the CS or
another technique could significantly reduce the
transfusion rate (0.39/0.7) [2] by 25% with an alpha
error of 0.05 and a power of 80%, we would have
needed more than 100 000 patients in each group.
Therefore, we are limited to observational studies or
historical controls to investigate transfusion strategies
in our center. This survey is a study with historical
controls [15], where 2 groups of 75 patients were
compared. We evaluated CS to limit allogenic RBC
transfusion at a time that corresponded with the
Table I. Groups comparison according to variables that could influence the blood loss or RBC transfusion rate.
Variables
All patients
(patients 1150)
Period 1
(patients 175)
Period 2
(patients 76150) p value
Gender (male) 66.7% 64.7% 68.7% NS
Age (years) 529/12 519/12 529/12 NS
Weight (kg) 749/12 719/18 779/18 NS
Height (cm) 1689/10 1689/10 1699/9 NS
Starting Hb value (g/L) 107.09/23.4 105.79/22.5 108.59/24.3 NS
Starting INR value 1.89/0.9 1.79/0.7 1.89/1.1 NS
Starting platelet count (109 platelets/L) 999/58 1029/64 959/54 NS
Pugh’s score 9.79/2.5 9.59/2.2 9.99/2.7 NS
MELD score 179/9 179/8 179/9 NS
Starting creatinine value (mmol/L) 1019/58 979/56 1069/59 NS
% of use of phlebotomy 42.0% 45.3% 38.7% NS
% of use of cell salvage 32.6% 0 65.3%* B/0.0001
Values are given as mean9/SD or percentage. Hb, hemoglobin; INR, international normalized ratio; MELD, model of end-stage liver
disease; creatinine, serum creatinine.
*CS was used for each OLT, but there was enough blood to retransfuse in 65.3% of the cases in period 2.
Table II. Surgical characteristics of all patients.
Variables All patients (patients 1150) Period 1 (patients 175) Period 2 (patients 76150) p value
RBC transfused (units per patient) 0.49/1.0 0.49/0.9 0.49/1.2 NS
Threshold for RBC transfusion (g/L) 56.59/8.3 57.09/7.5 55.79/8.6 NS
Final Hb value (g/L) 89.59/19.0 85.29/17.8 93.89/19.3 B/0.0001
CVP before clamping (mmHg) 6.49/3.8 6.99/4.2 5.89/2.5 NS
Blood loss (ml) 11149/556 8189/302 14109/603 B/0.0001
Crystalloids before clamping (ml) 10589/329 9869/251 11349/383 NS
Diuresis (ml/kg/h) 1.99/1.7 1.89/1.3 1.99/1.7 NS
Length of surgery (min) 2449/65 2259/57 2669/68 B/0.0001
% of cases without any blood products 80.0% 78.7% 81.3% NS
Values are given as mean9/SD. RBC, red blood cells; Hb, hemoglobin; CVP, central venous pressure.
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arrival of two junior surgeons and eventually an
increase in blood loss.
Maturity [15] or experience (surgeon skill) was not
a bias with potential impact on external validity, as
two new surgeons joined the transplant team.
Furthermore, the transfusion rate did not change
with time.
The overall transfusion rate was 0.49/1.0 RBC
units per patients. It could be argued that our patients
were not very sick according to the model of end-stage
liver disease (MELD) score. The MELD score is a
combination of the starting INR value, serum creati-
nine, and bilirubin [18]. It has been created to
evaluate liver insufficiency more objectively than the
Pugh’s score that evaluates the severity of cirrhosis.
MELD score is used mostly in USA to prioritize
OLTs but not in Canada. So, it is not surprising that
USA recipients for OLT might have an increased
MELD score.
The MELD scores have been the same since 1998 for
more than 450 patients in our center and the transfu-
sion rate went from 2.89/3.5 RBC per patient with
4.19/4.0 units of plasma per patient [19] to 0.39/0.7
RBC units per patient without any plasma [2].
The purpose of our study was not to compare the
level of morbidity between our patients and patients
from other centers. We wanted to evaluate CS in
patients with a comparable disease severity. Our
patients, when compared to other series, seem to be
as sick if not sicker. In the study by Frasco et al. [18],
patients with a RBC transfusion rate of 2.99/2.7 RBC
units per patient (total of 18 units of allogenic blood
products per patient) had the same severity of disease
as our patients. In the study by Ramos et al. [19],
patients with the same transfusion rate of 2.99/2.9
RBC units per patient had a starting INR value of
1.29/0.2. In our series, 86 patients had a starting INR
value of 1.5 or more and just 1 of these patients
received plasma (1 unit). Moreover, 28 patients had a
starting platelet count lower than 50/109 platelets/L
and none received any platelets.
Patients from the two study periods were identical
in all respects. There was no change in the transfusion
rate from period 1 to 2: 0.49/0.9 vs 0.49/1.2 RBC
units per patient (Table II), the threshold for transfu-
sion, and the percentage of cases without transfusion
of any blood products was also similar, 78.7% vs
81.3%. The length of surgery was higher in period 2,
after the arrival of surgeons 5 and 6 (Tables II and
III). Previously, we noted that when surgeons were
compared, the length of surgery was an independent
factor for RBC transfusions [20]. This suggests that
blood loss increases with the length of surgery. That
was the case in our prospective survey. Blood loss,
which was difficult to assess with accuracy, was higher
in period 2 (the amount of blood was determined by
adding the blood loss suctioned from the CS and
sponges). As two surgeons always operated as a team
and a junior surgeon was always teamed with a senior,
blood loss could have been higher.
The arrival of two surgeons and the increase in
blood loss did not modify the transfusion rate with the
use of the CS and the final Hb value was higher in
period 2 than in period 1 (Table II). In period 1, with
a mean blood loss of 818 ml, the starting Hb value
dropped from 105.7 g/L to 85.2 g/L, a decrease of
20.5 g/L. In period 2, we should have expected from a
blood loss of 1410 ml and the same transfusion rate
as for period 1, a drop in the starting Hb value of
35.3 g/L (1410 ml/20.5 g/L/818 ml). The final
Hb value should have been 73 g/L, and we obtained
94 g/L. The CS saved a mean of 21 g/L of Hb per
patient. The mean blood volume of patients was
around 5.8 L (77 kg/75 ml/kg), so the CS has saved
122 g of Hb per patient (5.8 L/21 g/L). One unit of
300 ml of allogenic RBC contains around 70 g of Hb.
To obtain a final Hb of 94 g/L without the use of
the CS, we should have transfused 1.7 RBC units
(122 g/70 g/RBC unit); therefore, the CS saved about
1.7 RBC units per patient. In the province of Que´bec,
one unit of RBC costs around C$500. Therefore, a
mean of C$1000 was saved for each OLT. If we look
at the CS: the perfusionist’s cost was C$125 per case
with C$175 for equipment (tubing for suction, $30;
reservoir, $53 for all cases; and washing: $92 ($142
for 65% of the cases), and the company (Ryan
Medical) provided us with the CS device). The CS
saved around C$700 for each OLT.
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Figure 2. Patient stratification by number of intraoperative RBC
units transfused for period 1 (patients 175).
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Figure 3. Patient stratification by number of intraoperative RBC
units transfused for period 2 (patients 76150).
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Kemper et al. [14] in 1997 encountered different
expenses that would include the cost of the CS device
and allogenic RBC units at other given prices. So,
they stated about the break-even point of 12.6 RBC
units transfused to be cost-effective. In our center the
break-even point is 0.67 RBC units: prices for 2006
have changed and were applied to this study. We
doubt the statement by de Boer et al. [13] that ‘the
low amount of blood loss encountered in recent years
no longer allows cost-effective use of the CS’. It
should be pertinent to reassess cost-effectiveness of
the series already studied according to today’s prices.
Before this study, we could guess that the CS would
compensate for a possible increase of blood loss with
the arrival of two new surgeons. That was the case and
more. The starting Hb value was the same for both
periods; blood loss was higher in period 2 with the
same transfusion rate (mean RBC transfusion, per-
centage without blood products, threshold of RBC
transfusions), yet the final Hb value was higher in
period 2 (Table II). The threshold for RBC transfu-
sions was lower in this study (56.5 g/L) than the one
chosen in our protocol (68 g/L) because the anesthe-
siologists aimed at transfusing after the bleeding was
controlled, but the thresholds were the same for both
periods.
The CS is a tool that decreases the transfusion of
allogenic RBC units. In our center, with a transfusion
rate of 0.39/0.7 RBC units per patient [2], with 79%
of OLTs without blood products, it is difficult to
evaluate a strategy aimed at decreasing blood loss or
the transfusion rate. To use the CS, we need
significant blood loss to prime it. After suctioning
blood from the operating field, the blood is washed,
and concentrated for retransfusion at a Ht value
between 0.7 and 0.8. If the starting Ht value is 0.4,
for each blood volume lost, we should retransfuse with
an Ht of 0.8, at best, half of the blood volume
suctioned. If the starting Ht is 0.2, for each blood
volume lost, we will be able to retransfuse one-quarter
of the blood loss. To be useful, the CS needs
significant blood loss and a high starting Ht value.
Often, in our center, the higher the starting Hb value,
the smaller the blood loss. Nevertheless, the increase
in blood loss in period 2 permitted us to demonstrate
the utility of the CS in OLT in our center despite a
low transfusion rate. It should be easier for liver
transplantation centers with higher transfusion rates
to evaluate it prospectively.
Despite the conclusions reached by de Boer et al.
[13], in our series, the increase in blood loss was not
secondary to the CS during period 2 but its usefulness
was established in large blood loss. Moreover, the
study by de Boer et al. was retrospective, and a direct
causal relationship could not be verified between the
CS and increased blood loss. When we retransfuse a
large quantity of blood from the CS, it is like a massive
transfusion of allogenic RBC (transfusion of RBC
without coagulation factors and platelets). In both
cases, we transfuse blood without coagulation factors
and platelets. So we might encounter coagulation
disturbances.
Unlike many liver transplantation centers, we do
not control coagulation defects during surgery. In
spite of what Frasco et al. [17] stated and what we
found previously [19], baseline coagulation status is
no more a predictor of OLT without RBC transfusion
[6]. Furthermore, we did not find any advantage in
correcting coagulation defects before or during OLT.
In addition, some authors have found a significant link
between transfusion of plasma peroperatively and
decreased 1-year survival rate [21].
Table IV. Number of patients according to diagnoses.
Diagnosis Period 1 Period 2
Alcoholic cirrhosis 16 18
Sclerosing cirrhosis 12 4
Cryptogenic cirrhosis 12 4
Chronic hepatitis C virus 10 10
NASH 9 7
Hepatocarcinoma secondary to cirrhosis
B or C
5 13
Primary and secondary biliary cirrhosis 3 5
Chronic hepatitis B virus 3 4
Fulminant hepatitis A or B 2 1
Autoimmune hepatitis 1 3
Fulminant hepatitis secondary to
acetaminophen
1 3
Miscellaneous 1 3
Total 75 75
NASH, non-alcoholic steato-hepatitis; miscellaneous, hepatic artery
stenosis or thrombosis, biliary duct stenosis. Period 1, patients
175; Period 2, patients 76150.
Table III. Surgical characteristics detailed for two groups of surgeons: seniors vs juniors.
Variables Four senior surgeons (120 patients) Two junior surgeons (30 patients) p value
Starting Hb value (g/L) 1109/21 1039/30 NS
Length of surgery (min) 2319/54 2919/73 B/0.0001
% of utilization of cell salvage 36% 57% 0.03
CVP before clamping (mmHg) 5.79/3.7 4.79/2.4 NS
Blood loss (ml) 9789/719 13829/868 B/0.0001
RBC transfused (units per patient) 0.39/0.7 0.49/1.3 NS
Final Hb value (g/L) 899/19 859/16 NS
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We administered aprotinin according to the Ham-
mersmith protocol [16], a high-dose protocol. Some
randomized, controlled studies [5,22] have shown the
efficacy of aprotinin in reducing blood loss. Aprotinin
probably successfully limits fibrinolysis. We have used
it for more than 600 OLTs without any major
thromboembolic event [23,24]. It is difficult to
evaluate the utility of aprotinin in our center because
we have been using it since 1993 for all OLTs.
In conclusion, for 150 OLTs, despite increases in
the length of surgery and in blood loss, the transfusion
rate did not change after the introduction of the Cell
Saver after the 75th OLT. In all, 0.4 RBC units were
transfused per patient, 80% of patients did not receive
any blood product, and the final Hb value was found
to be higher in period 2 with use of the CS. We think
that the CS is helpful in cases with large blood loss,
and in our center with a low transfusion rate, it saved a
mean of 21 g/L of Hb per patient or two RBC unit
transfusions. Better yet, it was cost-effective. As long
as we cannot predict with accuracy which patients will
bleed, we will continue to use the CS for all OLTs.
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